Phase II Study of Irinotecan and Gemcitabine (IrinoGem) Combined With 3-D Conformal Radiation Therapy for Locally Advanced Pancreatic Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
time to treatment failure
Ron Epelbaum, MD
Principal Investigator
Israel: Israeli Health Ministry Pharmaceutical Administration
RonIrinoGem.CTIL
NCT00192712
November 2002
September 2010
Name | Location |
---|